{"contentid": 488064, "importid": NaN, "name": "MaaT to move microbiome drug into Phase III trial", "introduction": "French microbiome company MaaT Pharma has announced top-line results from a Phase II trial evaluating MaaT013 in a high-risk patient population with grade III-IV steroid-refractory, gastrointestinal-predominant acute graft-versus-host disease (SR-GI-aGvHD).", "content": "<p>French microbiome company MaaT Pharma has announced top-line results from a Phase II trial evaluating MaaT013 in a high-risk patient population with grade III-IV steroid-refractory, gastrointestinal-predominant acute graft-versus-host disease (SR-GI-aGvHD).</p>\n<p>The study met its primary endpoint of clinical efficacy, demonstrating a combined 33.3% complete response rate or very good partial response rate at day 28. In addition, the overall response rate was 38.1% at day 28 and the best overall response rate was 57.1%. MaaT013 also showed an acceptable safety profile.</p>\n<p><span class=\"pullQuote\">\"Validates our approach of restoring the microbial ecosystem to normalize the immune response\"</span>Based on the beneficial clinical outcomes and good safety profile observed to date in more than 70 patients treated as part of both the HERACLES trial and an early access program, MaaT plans to initiate a pivotal Phase III trial in GI-aGvHD with MaaT013.</p>\n<p>This therapy is a full-ecosystem, off-the-shelf, standardized, pooled-donor, high-richness microbiome biotherapeutic, in an enema formulation, characterized by a high diversity and consistent richness of microbial species.</p>\n<p>John Weinberg, chief medical officer at MaaT, said: &ldquo;Acute GvHD is a devastating disease and treatment is often limited to suppressing the patient&rsquo;s immune system. The therapeutic effect of our lead candidate MaaT013, especially in such a high-risk patient population, is very encouraging. It further validates our approach of restoring the microbial ecosystem to normalize the immune response.</p>\n<p>&ldquo;The HERACLES trial data, as well as the early access program results obtained in a larger and more diverse subpopulation of patients, demonstrate the real-life benefit MaaT013 can provide to these patients.&rdquo;&nbsp;</p>", "date": "2021-03-17 14:13:00", "meta_title": NaN, "meta_keywords": "MaaT, trial, response, microbiome, Phase, rate, disease, acute, results, high-risk, patient, population, drug, move, Pharma, announced, company, French", "meta_description": "French microbiome company MaaT Pharma has announced topline results from a Phase II trial evaluating MaaT013 in a high-risk patient population with grade III-IV", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-17 12:35:29", "updated": "2021-03-17 14:14:17", "access": NaN, "url": "https://www.thepharmaletter.com/article/maat-to-move-microbiome-drug-into-phase-iii-trial", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "maat_big.png", "image2id": "maat_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Hematology, Infectious diseases, Oncology", "topic_tag": "Drug Trial, Research", "geography_tag": "France", "company_tag": "MaaT Pharma", "drug_tag": "MaaT013", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-17 14:13:00"}